v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Jul. 31, 2026
Jul. 31, 2025
Operating expenses:        
Research and development $ 20,090 $ 22,575 $ 64,540 $ 62,758
General and administrative 13,924 7,372 32,627 20,926
Total operating expenses 34,014 29,947 97,167 83,684
Loss from operations 34,014 29,947 97,167 83,684
Other expenses (income), net:        
Interest income (2,401) (2,233) (7,804) (7,451)
Interest expense 843 758 2,320 2,244
Loss on extinguishment of debt     488  
Other expenses, net 45 280 309 448
Total other income, net (1,513) (1,195) (4,687) (4,759)
Net loss before income taxes 32,501 28,752 92,480 78,925
Provision for income taxes 0 239 0 497
Net loss 32,501 28,991 92,480 79,422
Other comprehensive loss (income):        
Unrealized loss (gain) on available-for-sale investments 210 240 463 (210)
Total comprehensive loss $ 32,711 $ 29,231 $ 92,943 $ 79,212
Net loss per share of common shares, basic $ 0.47 $ 0.57 $ 1.34 $ 1.56
Net loss per share of common shares, diluted $ 0.47 $ 0.57 $ 1.34 $ 1.56
Weighted-average common shares outstanding, basic [1] 69,734,610 51,097,711 68,898,554 51,031,618
Weighted-average common shares outstanding, diluted [1] 69,734,610 51,097,711 68,898,554 51,031,618
[1] Pre-funded warrants of 2,735,295 are included within the weighted-average number of common shares calculation for 2026.